Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Schrodinger Q1 Earnings Call Highlights
06.05.2026 02:07
Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti
Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises
05.05.2026 11:49
Competition from Eli Lilly puts pressure on margins despite strong early uptake
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
05.05.2026 10:45
New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years. These results will be presented at Digestive Disease Week® (DDW) and represent the first time an interleu
Novo Nordisk’s Weight-Loss Pill Momentum Faces Pricing Pressure
05.05.2026 10:27
Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.
Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
05.05.2026 06:56
Novo Nordisk is a Strong Buy as it transitions to a high-volume, lower-price model, leveraging operational efficiency and AI-driven savings. More on NVO stock.
Eli Lilly: No Big Gap To Competition
05.05.2026 06:29
Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest analysis of LLY stock.
3 Reasons It's Not Too Late to Buy Eli Lilly Stock
05.05.2026 00:50
The company still has a strong lead in its core therapeutic area.
Novo Nordisk Obesity Pill Momentum Meets Valuation Gap And Risk Flags
05.05.2026 00:19
Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...
Jim Cramer Praises Eli Lilly’s Performance
03.05.2026 15:51
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]
Results: Eli Lilly and Company Beat Earnings Expectations And Analysts Now Have New Forecasts
03.05.2026 13:05
Eli Lilly and Company ( NYSE:LLY ) investors will be delighted, with the company turning in some strong numbers with...
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling'
03.05.2026 12:01
Blockbuster sales of its flagship GLP-1 treatments have propelled Eli Lilly And Co.‘s first-quarter earnings, prompting a prominent Wall Street analyst to defend the stock’s valuation and highlight the disruptive potential of its new oral weight-loss drug. Fueling The ‘Love Affair’ Eli Lilly's revenue skyrocketed 56% year-over-year to $19.8 billion during its first-quarter 2026, driven primarily by the astronomical volume demand for its metabolic and weight-management medications. Following the
Inspire Medical Systems AGM: 2025 Revenue Hits $912M as Shareholders OK Governance, Equity Plan
03.05.2026 10:24
Inspire Medical Systems (NYSE:INSP) highlighted revenue growth, product innovation, and a series of governance and compensation-related items that won stockholder approval at its 2026 annual meeting held virtually on April 30, 2026. Management highlights 2025 performance and milestones Timothy P. H
Why Eli Lilly (LLY) Stock Is Trading Up Today
03.05.2026 09:08
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the company reported strong first-quarter 2026 financial results that surpassed analyst expectations and raised its full-year guidance.
ruist Reaffirms Buy on Eli Lilly (LLY) After Trial Success
03.05.2026 07:51
Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares on April 17, following encouraging Phase 3 trial outcomes for Foundayo in type 2 diabetes. Eli Lilly & Company (NYSE:LLY) reported the […]
Eli Lilly and Company Q1 Earnings Call Highlights
02.05.2026 01:05
Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly approved oral obesity therapy, and a slate of pipeline and business development milestones. Founday
Eli Lilly Strong Q1 Results Show Stable Pricing, Foundayo Volatility Remains, RBC Says
01.05.2026 18:36
Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid
Eli Lilly's Oral Weight-Loss Drug Gains Early Momentum as Prescriptions Surge, BofA Says
01.05.2026 17:49
Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, w
There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly
01.05.2026 16:46
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Assessing Eli Lilly (LLY) Valuation After A Strong Multi Year Share Price Run
01.05.2026 16:19
Assessing Eli Lilly after a strong multi year run Eli Lilly (LLY) is back in focus for many investors after a long stretch of strong multi year total returns and significant scale, with a market value around US$761.7b and annual revenue of US$65.2b. See our latest analysis for Eli Lilly. The latest 9.8% 1 day share price return takes Eli Lilly to US$934.60, while the 1 year total shareholder return of 18.56% and 5 year total shareholder return above 4x suggest long term momentum has remained...
Novo Launches Ozempic Pills Across 70,000 US Pharmacies
01.05.2026 15:40
Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.